NO20073651L - Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi - Google Patents

Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi

Info

Publication number
NO20073651L
NO20073651L NO20073651A NO20073651A NO20073651L NO 20073651 L NO20073651 L NO 20073651L NO 20073651 A NO20073651 A NO 20073651A NO 20073651 A NO20073651 A NO 20073651A NO 20073651 L NO20073651 L NO 20073651L
Authority
NO
Norway
Prior art keywords
therapy
autoimmune disease
patients
antiangiogenesis
failed previous
Prior art date
Application number
NO20073651A
Other languages
English (en)
Norwegian (no)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20073651L publication Critical patent/NO20073651L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073651A 2004-12-17 2007-07-16 Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi NO20073651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17
PCT/US2005/045600 WO2006066086A1 (en) 2004-12-17 2005-12-16 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Publications (1)

Publication Number Publication Date
NO20073651L true NO20073651L (no) 2007-09-10

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073651A NO20073651L (no) 2004-12-17 2007-07-16 Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi

Country Status (23)

Country Link
US (2) US20060134111A1 (es)
EP (1) EP1824885A1 (es)
JP (1) JP2008524241A (es)
KR (1) KR20070086218A (es)
CN (1) CN101120020A (es)
AR (1) AR052056A1 (es)
AU (1) AU2005316403A1 (es)
BR (1) BRPI0518105A (es)
CA (1) CA2587932A1 (es)
CR (1) CR9181A (es)
IL (1) IL183347A0 (es)
MA (1) MA29366B1 (es)
MX (1) MX2007007165A (es)
NO (1) NO20073651L (es)
NZ (1) NZ555286A (es)
PE (1) PE20061075A1 (es)
RU (1) RU2007126970A (es)
SG (1) SG158089A1 (es)
SV (1) SV2006002342A (es)
TN (1) TNSN07191A1 (es)
TW (1) TW200634026A (es)
WO (1) WO2006066086A1 (es)
ZA (1) ZA200704898B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201009A2 (en) * 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
EP1804835B9 (en) * 2004-09-13 2010-09-29 Genzyme Corporation Multimeric constructs
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010054221A2 (en) * 2008-11-06 2010-05-14 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
EP4169951A1 (en) * 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2009331955B2 (en) * 2008-12-23 2015-09-24 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MX2016012779A (es) * 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
EP3056216B1 (en) * 2015-02-11 2017-02-01 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with bevacizumab
KR20200130403A (ko) 2018-03-09 2020-11-18 아게누스 인코포레이티드 항-cd73 항체 및 그의 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
CR9181A (es) 2008-07-31
PE20061075A1 (es) 2006-11-15
MX2007007165A (es) 2007-08-14
RU2007126970A (ru) 2009-01-27
SV2006002342A (es) 2006-06-01
US20060134111A1 (en) 2006-06-22
JP2008524241A (ja) 2008-07-10
IL183347A0 (en) 2007-09-20
MA29366B1 (fr) 2008-04-01
TNSN07191A1 (en) 2008-11-21
TW200634026A (en) 2006-10-01
CA2587932A1 (en) 2006-06-22
US20080214789A1 (en) 2008-09-04
NZ555286A (en) 2010-04-30
ZA200704898B (en) 2009-03-25
KR20070086218A (ko) 2007-08-27
CN101120020A (zh) 2008-02-06
WO2006066086A1 (en) 2006-06-22
BRPI0518105A (pt) 2008-11-04
AU2005316403A1 (en) 2006-06-22
EP1824885A1 (en) 2007-08-29
AR052056A1 (es) 2007-02-28
SG158089A1 (en) 2010-01-29

Similar Documents

Publication Publication Date Title
NO20073651L (no) Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi
NO20054371L (no) Somatostatin-dopamin kimaere analoger
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
RS54156B1 (en) COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
NO20060871L (no) Azepinderivater som farmasoytiske midler
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20064771L (no) 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112017007545A2 (pt) derivados de carbazol
EA201591055A1 (ru) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
EA201691278A1 (ru) Замещенные пиперидинил-тетрагидрохинолины
EA201071146A1 (ru) Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application